ArticleNature medicine2019
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 2 pooled it
18.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
228 citing papers in PubMed, 2 syntheses or guidelines pooled it, 312 citations in OpenAlex.
- A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.Journal for immunotherapy of cancer · 2021Pooled it
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study.Blood advances · 2026Trial
- Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.Blood neoplasia · 2025Trial
- A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.Nature communications · 2025Trial
- Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Trial
- Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions.Annals of medicine · 2026Review
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Current status and challenges of TCR-T cell therapy for AML/MDS.International journal of hematology · 2026Review
- Minor histocompatibility antigen TCR-T.Blood advances · 2026Review
- Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood reviews · 2026Review
- MHC Attention: Identifying HLA-E presented cancer antigens through deep learning and high-throughput screening.bioRxiv : the preprint server for biology · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Strategies to eliminate native T cell receptors for adoptive T cell therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- T-cell repertoire response in individuals with post-acute sequelae of COVID-19.bioRxiv : the preprint server for biology · 2026Article
168 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 4 institutions in 3 countries.
Aude G Chapuis *Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9574-5448
Daniel N Egan *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Merav Bar *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Thomas M SchmittProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Megan S McAfeeProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kelly G PaulsonProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Valentin VoilletVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Raphael GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gunnar B RagnarssonProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Marie BleakleyProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cecilia C YeungClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Petri MuhlhauserUniversity of Washington School of Medicine, Seattle, WA, USA.
Hieu N NguyenProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lara A KroppProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Luca CastelliProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Felecia WagenerProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Daniel HunterProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Marcus LindbergProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kristen CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8901-9941
Aaron SeeseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M Juliana McElrathClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Natalie DuerkoppProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ted A GooleyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Philip D GreenbergProgram in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. pgreen@u.washington.edu.ORCID http://orcid.org/0000-0003-3812-647X
Fred Hutch Cancer Center · USUniversity of Washington · USAlpine Immune Sciences (United States) · USReykjavík University · IS
Funding
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4MTargeting Leukemia with Memory CD8+ T cells Transduced to Express High-Affinity WK08CA169485 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHAPUIS, AUDE · 2013 to 2017
$857kNCI NIH HHS K08 CA169485NCI NIH HHS P01 CA018029
Abstract
Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features
Indexed as
Genes, T-Cell ReceptorAdultAgedFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedRecurrenceTransplantation, HomologousWT1 ProteinsWT1 Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.